Cetuximab-capped mesoporous silica NP (MP-SiO2 NP) loaded with gefitinib, proved to be of higher efficiency in inhibition of cell growth, in EGFR-mutant NSCLC with gefitinib-resistant cell line derived from PC9 cell (PC9-DR), than gefitinib alone. This evidence concerns the gene EGFR and non-small cell lung carcinoma.